Clinical Trials

This year, International Clinical Trials Day (ICTD) 2019 takes place on 20 May and to mark the occasion, the National Institute for Health Research NIHR will be introducing its new Be Part of Research campaign. The intention of the campaign is to promote involvement in research to patients, carers and the public. The campaign will

Sanofi has announced the dosing of their first patient in a Phase IIb clinical trial being conducted to assess SAR442168 (formerly known as PRN2246) for the treatment of relapsing multiple sclerosis. The launch of the trial triggers a $30m milestone payment to Principia Biopharma, which has partnered with Sanofi to develop the drug candidate in

The pharmaceutical industry is undoubtedly a major contributor to the UK economy, whilst also providing and developing life-saving and life enhancing medicines to patients. However, in recent years many within the industry have witnessed a lack of skilled young researchers entering the profession. For the pharmaceutical sector to prevail (especially in such turbulent times) it

Recent trial data has shown that AstraZeneca’s Dapagliflozin cut the relative risk of major adverse cardiovascular events (MACE) by 16% compared to placebo in patients with type II diabetes who had a prior heart attack. In a second pre-specified sub-analysis of data from the DECLARE-TIMI 58 study, the SGLT2 inhibitor reduced the relative risk of

The Clinical Professionals group aim to be aware of the latest industry events and news whilst also aspiring to be at the forefront of the latest analytics and reporting. This enables our consultants to provide a concise and quality service for both clients and candidates, whilst helping the industry to evolve as a whole. Consequently,

As it is Healthcare Science Week we would like to shout out about our fully funded, award winning Graduate Training Academy for those looking to get their first in industry role within clinical trials. We are extremely proud that it has Science Council employer champion status and has won multiple industry awards for innovation. The

Recently Novartis has been keen to demonstrate its digital progress so far, and ahead of today’s full year results conference at its HQ in Basel, Switzerland, it showcased some of its advances to the media. One of its most noteworthy achievements is the new digitally-enabled nerve centre on its Basel campus which allows the company to monitor

Lilly have reported positive results from two Phase lll trials, PRONTO-T1D and PRONTO-T2D, which examined the safety and efficacy of Ultra Rapid Lispro (URLi) compared to insulin lispro to treat people with type 1 and type 2 diabetes. The trial met the primary efficacy endpoint of non-inferior A1C reduction from baseline compared to insulin lispro

AstraZeneca has reported positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) of BMS-512148 compared to placebo for the treatment of patients with type 2 diabetes (T2D). The trial had met its primary safety objective of non-inferiority for major adverse cardiovascular events (MACE). The trial also achieved one of its two

Eli Lilly and Company (Lilly) has commenced the IXORA-R head-to-head (H2H) clinical trial to investigate the efficacy and safety of ixekizumab when compared to guselkumab to treat adult patients with moderate-to-severe plaque psoriasis. Roughly 960 patients are expected to be included in the 24-week, multicentre, randomised, blinded, parallel-group trial. The trial’s primary objective is the